NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Artificial Tears Industry
http://www.reportlinker.com/p0960376/Global-Artificial-Tears-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Ophthalmic_Devices
This report analyzes the worldwide markets for Artificial Tears in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 28 companies including many key and niche players such as Abbott Medical Optics, Inc., Allergan, Inc., Advanced Vision Research, Inc., Bausch & Lomb, McNEIL-PPC, Inc., Novartis International AG, Alcon, Inc., Santen Pharmaceuticals Co, Ltd., and Novagali Pharma S.A. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Table 1: Global Ophthalmology Market (2011): Percentage Share
Breakdown by Product Segment- Ophthalmics, Glaucoma,
Artificial Tears, Ocular Allergy, Plain Ocular
Anti-Infectives and Ophthalmic NSAIDs (includes corresponding
Graph/Chart) II-1
Table 2: Prevalence of Dry Eye Condition in the US (2011) (
includes corresponding Graph/Chart) II-2
Industry Dynamics II-2
Over-The-Counter (OTC) Preparations II-2
Dry Eye - An Underreported and Undertreated Condition II-3
Current and Future Analysis II-3
Opportunities Abound in Developing Countries II-4
Lack of Clear Product Differentiation Leads to Confusion II-4
2. KEY ISSUES & TRENDS II-5
Aging Population and Women Constitute Major Customers II-5
Increased Usage of Computers and Contact Lens Drives Market
Growth II-5
Drug Formulation Fraught with Difficulties II-5
Low Patent Compliance Limits Market Opportunities II-5
OTC Products Witness Robust Demand II-6
Preservative-Free Artificial Tears Gain Popularity II-6
Prescription Dry Eye Products Market- Highly Concentrated II-6
Direct-to-Customer Promotions: A Key Marketing Strategy II-7
3. OPHTHALMIC DRUGS MARKET - AN OVERVIEW II-8
Ophthalmic Diseases II-8
Table 3: Global Ophthalmic Market (2011): Percentage
Breakdown of Revenues by Market Verticals- Eye Care
Pharmaceuticals, Contact Lens, Cataract Surgery, Contact
Solutions and Refractive Surgery (includes corresponding
Graph/Chart) II-8
Major Ophthalmic Disease Conditions II-9
Leading Ophthalmic Products II-9
Table 4: Leading Players in the Global Eye Care Market
(2010): Percentage Share Breakdown of Sales for Alcon,
Novartis, Bausch & Lomb, and Others (includes corresponding
Graph/Chart) II-10
Business Opportunities in Ophthalmology: Key Pointers II-11
New Drugs and Technological Developments Sustain Momentum II-11
Patent Expiries to Challenge Growth in Ophthalmic Drugs Market II-11
Product Innovations Go A Long Way in Helping Patients II-12
Medical Reimbursements: Critical to Commercial Success II-12
Mapping The Future of Ophthalmic Drug Delivery II-13
4. DRY EYE SYNDROME - INDUSTRY DYNAMICS II-14
Multi-Factorial Nature of Dry Eye Poses Challenges to Drug Makers II-14
Bridging Chasm Between Diagnosis and Treatment of Dry Eye
Syndrome II-14
Novel Approaches to Revolutionize Dry Eye Therapy II-15
Anti-Inflammatory Drugs II-15
Mucin Secretagogues II-15
Hormonal Therapies II-16
Omega-3 Drugs II-16
Muco-Mimetics II-16
Barrier-function Drugs II-16
Pipeline Drug Candidates for Treatment of Dry Eyes II-16
5. PRODUCT OVERVIEW II-18
Dry Eye - A Common Ophthalmic Condition II-18
Causes of Dry Eyes II-18
Treatment Strategies II-19
Artificial Tears - A Brief Overview II-19
Product Options for Dry Eye Syndrome: Breakdown by Palliative
Therapies and Targeted Therapies II-20
KCS Inflammation Cycle II-21
Common Symptoms of KCS II-21
Risk Information II-21
Impact of Dry Eye Syndrome on Routine Daily Life Activities:
Ranking based on Intensity of Impact Felt by Patients II-22
Types of Artificial Tears II-22
Artificial Tears Usage and Dosage II-22
Drug Contraindications or Interactions II-23
Osmolarity II-23
Table 5: Osmolarity of Select Ocular Brands (includes
corresponding Graph/Chart) II-23
Alternate Treatment Methods II-24
6. PRODUCT INTRODUCTIONS/INNOVATIONS II-25
Santen to Introduce Sante Medical Guard, OTC Eye Drop II-25
Alcon Launches Systane® BALANCE Lubricant Eye Drops II-25
Santen Pharmaceutical Rolls Out Dry Eye Treatment DIQUAS
Ophthalmic Solution 3% II-25
Moorfields Pharmaceuticals Launches HydromoorTM 0.3% Hypromellose II-26
7. RECENT INDUSTRY ACTIVITY II-27
Bausch + Lomb Acquires ISTA Pharmaceuticals II-27
TearLab Osmolarity System Receives FDA Waiver II-27
Novartis, Alcon and CIBA VISION Merge II-27
Merck Takes Over Inspire Pharmaceuticals II-28
Santen Pharmaceutical Acquires Majority Stake in Novagali
Pharma SA II-28
Akorn Takes Over Advanced Vision Research II-28
OCuSOFT Inks Exclusive Long-Term Distribution Agreement with
Ardeo Health II-28
Santen Establishes Subsidiary in India II-29
ISTA Pharmaceuticals Announces Positive Test Results for REMURA™ II-29
Bausch + Lomb Recalls Soothe® Xtra Protection (XP) Eyedrops II-29
Inspire Pharma and Santen Obtain Approval for Diquas in Japan II-29
Allergan and Inspire Amend Agreement for Distribution of
Prolacria II-30
Resolvyx Pharmaceuticals Signs Option Agreement with Celtic
Therapeutics II-30
Moorfields Pharmaceuticals Takes Over Ilube 5% w/v Eye Drops
from Alcon Laboratories II-30
Novartis International Acquires Majority Stake in Alcon from
Nestle II-31
TearLab and Abbot Medics Forge Marketing Agreement II-31
Allergan Receives Approval from Health Canada for Restasis II-31
Alcon Signs Collaborative Research Agreement with AstraZeneca II-31
Abbott Takes Over Advanced Medical Optics II-32
Abbott Medical Optics Takes Over Visiogen II-32
8. FOCUS ON SELECT GLOBAL PLAYERS II-33
Abbott Medical Optics, Inc. (US) II-33
Allergan, Inc. (US) II-33
Advanced Vision Research, Inc (US) II-34
Bausch & Lomb (US) II-34
McNEIL-PPC, Inc (US) II-34
Novartis International AG (Switzerland) II-35
Alcon, Inc. (Switzerland) II-35
Santen Pharmaceuticals Co, Ltd. (Japan) II-35
Novagali Pharma S.A. (France) II-36
9. GLOBAL MARKET PERSPECTIVE II-37
Table 6: World Recent Past, Current & Future Analysis for
Artificial Tears by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 Through 2018 (includes corresponding
Graph/Chart) II-37
Table 7: World Historic Review for Artificial Tears by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2004
Through 2009 (includes corresponding Graph/Chart) II-38
Table 8: World 15-Year Perspective for Artificial Tears by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets for Years 2004, 2011 &
2018 (includes corresponding Graph/Chart) II-39
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Recession Rejuvenates Sales of Pharmaceutical OTC Drugs III-1
Restasis- The Undisputed Leader III-1
US Artificial Tears Market (2011): Ranking of III-2
Leading Brands- Tears Naturale, HypoTears and Refresh Plus III-2
Patent Expiry Status for Leading Ophthalmic Brands III-2
Table 9: Prevalence of Dry Eye in the United States for the
Years 2006, 2009 and 2012 (In Millions of Individuals)
(includes corresponding Graph/Chart) III-3
Table 10: Number of Individuals Treated for Dry Eye in the
United States (In 000s) for the Years 2006, 2009 & 2012
(includes corresponding Graph/Chart) III-3
Strategic Corporate Developments III-3
Select Players III-7
B.Market Analytics III-10
Table 11: US Recent Past, Current & Future Analysis for
Artificial Tears Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2010 Through 2018
(includes corresponding Graph/Chart) III-10
Table 12: US Historic Review for Artificial Tears Market
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 Through 2009 (includes corresponding
Graph/Chart) III-11
2. CANADA III-12
A.Market Analysis III-12
Current and Future Analysis III-12
Strategic Corporate Development III-12
B.Market Analytics III-13
Table 13: Canadian Recent Past, Current & Future Analysis
for Artificial Tears Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2010 Through
2018 (includes corresponding Graph/Chart) III-13
Table 14: Canadian Historic Review for Artificial Tears
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2004 Through 2009 (includes
corresponding Graph/Chart) III-14
3. JAPAN III-15
A.Market Analysis III-15
Current and Future Analysis III-15
Product Introduction/Innovation III-15
Strategic Corporate Developments III-16
Select Players III-16
B.Market Analytics III-18
Table 15: Japanese Recent Past, Current & Future Analysis
for Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 Through 2018 (includes corresponding
Graph/Chart) III-18
Table 16: Japanese Historic Review for Artificial Tears
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2004 Through 2009 (includes
corresponding Graph/Chart) III-19
4. EUROPE III-20
A.Market Analysis III-20
Current and Future Analysis III-20
Ophthalmic Pharmaceutical Drugs Market in Europe III-20
Artificial Tears Reimbursement Overview III-20
Strategic Corporate Developments III-20
Product Introductions/Innovations III-21
Select Players III-22
B.Market Analytics III-23
Table 17: European Recent Past, Current & Future Analysis
for Artificial Tears by Geographic Region - France, Germany,
Italy, UK, Spain and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2010 Through 2018 (includes corresponding Graph/Chart) III-23
Table 18: European Historic Review for Artificial Tears by
Geographic Region - France, Germany, Italy, UK, Spain and
Rest of Europe Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2004 Through 2009
(includes corresponding Graph/Chart) III-24
Table 19: European 15-Year Perspective for Artificial Tears
by Geographic Region - France, Germany, Italy, UK, Spain and
Rest of Europe Markets for Years 2004, 2011 & 2018 (includes
corresponding Graph/Chart) III-25
4a. FRANCE III-26
A.Market Analysis III-26
Current and Future Analysis III-26
B.Market Analytics III-26
Table 20: French Recent Past, Current & Future Analysis for
Artificial Tears Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2010 Through 2018
(includes corresponding Graph/Chart) III-26
Table 21: French Historic Review for Artificial Tears Market
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 Through 2009 (includes corresponding
Graph/Chart) III-27
4b. GERMANY III-28
A.Market Analysis III-28
Current and Future Analysis III-28
B.Market Analytics III-28
Table 22: German Recent Past, Current & Future Analysis for
Artificial Tears Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2010 Through 2018
(includes corresponding Graph/Chart) III-28
Table 23: German Historic Review for Artificial Tears Market
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 Through 2009 (includes corresponding
Graph/Chart) III-29
4c. ITALY III-30
A.Market Analysis III-30
Current and Future Analysis III-30
B.Market Analytics III-30
Table 24: Italian Recent Past, Current & Future Analysis for
Artificial Tears Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2010 Through 2018
(includes corresponding Graph/Chart) III-30
Table 25: Italian Historic Review for Artificial Tears
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2004 Through 2009 (includes
corresponding Graph/Chart) III-31
4d. THE UNITED KINGDOM III-32
A.Market Analysis III-32
Current and Future Analysis III-32
Strategic Corporate Developments III-32
Product Introduction/Innovation III-32
B.Market Analytics III-33
Table 26: UK Recent Past, Current & Future Analysis for
Artificial Tears Analyzed with Annual Sales Figures in US$
Million for Years 2010 Through 2018 (includes corresponding
Graph/Chart) III-33
Table 27: UK Historic Review for Artificial Tears Market
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 Through 2009 (includes corresponding
Graph/Chart) III-34
4e. SPAIN III-35
A.Market Analysis III-35
Current and Future Analysis III-35
B.Market Analytics III-35
Table 28: Spanish Recent Past, Current & Future Analysis for
Artificial Tears Analyzed with Annual Sales Figures in US$
Million for Years 2010 Through 2018 (includes corresponding
Graph/Chart) III-35
Table 29: Spanish Historic Review for Artificial Tears
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2004 Through 2009 (includes
corresponding Graph/Chart) III-36
4f. REST OF EUROPE III-37
A.Market Analysis III-37
Current and Future Analysis III-37
B.Market Analytics III-37
Table 30: Rest of Europe Recent Past, Current & Future
Analysis for Artificial Tears Market Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2010
Through 2018 (includes corresponding Graph/Chart) III-37
Table 31: Rest of Europe Historic Review for Artificial
Tears Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2004 Through 2009 (includes
corresponding Graph/Chart) III-38
5. ASIA-PACIFIC III-39
A.Market Analysis III-39
Current and Future Analysis III-39
Opportunities Abound for Indian OTC Market III-39
B.Market Analytics III-40
Table 32: Asia-Pacific Recent Past, Current & Future
Analysis for Artificial Tears Market Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2010
Through 2018 (includes corresponding Graph/Chart) III-40
Table 33: Asia-Pacific Historic Review for Artificial
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 Through 2009 (includes corresponding
Graph/Chart) III-41
6. LATIN AMERICA III-42
A.Market Analysis III-42
Current and Future Analysis III-42
B.Market Analytics III-42
Table 34: Latin America Recent Past, Current & Future
Analysis for Artificial Tears Market Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2010
Through 2018 (includes corresponding Graph/Chart) III-42
Table 35: Latin America Historic Review for Artificial Tears
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2004 Through 2009 (includes
corresponding Graph/Chart) III-43
7. REST OF WORLD III-44
A.Market Analysis III-44
Current and Future Analysis III-44
B.Market Analytics III-44
Table 36: Rest of World Recent Past, Current & Future
Analysis for Artificial Tears Analyzed with Annual Sales
Figures in US$ Million for Years 2010 Through 2018 (includes
corresponding Graph/Chart) III-44
Table 37: Rest of World Historic Review for Artificial Tears
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2004 Through 2009 (includes
corresponding Graph/Chart) III-45
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 28 (including Divisions/Subsidiaries - 38)
The United States (24)
Canada (2)
Japan (1)
Europe (6)
- France (1)
- The United Kingdom (2)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (5)
To order this report:
Ophthalmic_Devices Industry: Global Artificial Tears Industry
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article